Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pirin is a prognostic marker of human melanoma that dampens the proliferation of malignant cells by downregulating JARID1B/KDM5B expression.
Penas C, Arroyo-Berdugo Y, Apraiz A, Rasero J, Muñoa-Hoyos I, Andollo N, Cancho-Galán G, Izu R, Gardeazabal J, Ezkurra PA, Subiran N, Alvarez-Dominguez C, Alonso S, Bosserhoff AK, Asumendi A, Boyano MD. Penas C, et al. Among authors: izu r. Sci Rep. 2023 Jun 12;13(1):9561. doi: 10.1038/s41598-023-36684-2. Sci Rep. 2023. PMID: 37308689 Free PMC article.
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Bissonnette R, et al. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. Lancet. 2024. PMID: 39033766 Clinical Trial.
Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab.
Gracia Cazaña T, Riera Monroig J, Izu R, Yanguas I, Lorda Espés M, Sánchez Salas MP, García Gil MF, Navarro Bielsa A, Aldea Manrique B, Almenara Blasco M, García-Latasa de Araníbar FJ, Fuentelsaz V, Morales Callaghan A, Ara-Martín M. Gracia Cazaña T, et al. Among authors: izu r. JAAD Int. 2024 Apr 7;16:66-71. doi: 10.1016/j.jdin.2024.02.019. eCollection 2024 Sep. JAAD Int. 2024. PMID: 38774344 Free PMC article.
Computational and Experimental Evaluation of the Immune Response of Neoantigens for Personalized Vaccine Design.
Malaina I, Gonzalez-Melero L, Martínez L, Salvador A, Sanchez-Diez A, Asumendi A, Margareto J, Carrasco-Pujante J, Legarreta L, García MA, Pérez-Pinilla MB, Izu R, Martínez de la Fuente I, Igartua M, Alonso S, Hernandez RM, Boyano MD. Malaina I, et al. Among authors: izu r. Int J Mol Sci. 2023 May 19;24(10):9024. doi: 10.3390/ijms24109024. Int J Mol Sci. 2023. PMID: 37240369 Free PMC article.
Melanoma Clinical Decision Support System: An Artificial Intelligence-Based Tool to Diagnose and Predict Disease Outcome in Early-Stage Melanoma Patients.
Diaz-Ramón JL, Gardeazabal J, Izu RM, Garrote E, Rasero J, Apraiz A, Penas C, Seijo S, Lopez-Saratxaga C, De la Peña PM, Sanchez-Diaz A, Cancho-Galan G, Velasco V, Sevilla A, Fernandez D, Cuenca I, Cortes JM, Alonso S, Asumendi A, Boyano MD. Diaz-Ramón JL, et al. Among authors: izu rm. Cancers (Basel). 2023 Apr 6;15(7):2174. doi: 10.3390/cancers15072174. Cancers (Basel). 2023. PMID: 37046835 Free PMC article.
Association of TYR SNP rs1042602 with Melanoma Risk and Prognosis.
Sevilla A, Sánchez-Diez A, Cobo S, Izagirre N, Martinez-Cadenas C, Martí RM, Puértolas T, de Unamuno B, Bañuls J, Izu R, Gardeazabal J, Asumendi A, Boyano MD, Alonso S. Sevilla A, et al. Among authors: izu r. Life (Basel). 2022 Dec 1;12(12):2004. doi: 10.3390/life12122004. Life (Basel). 2022. PMID: 36556369 Free PMC article.
Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years.
Falkenhain-López D, Muniesa C, Estrach MT, Morillo-Andújar M, Peñate Y, Acebo E, Pujol RM, García-Muret MP, Machan S, Medina S, Botella-Estrada R, Fernández de Misa R, Blanes M, Flórez A, Pérez-Paredes G, Izu R, Yanguas I, Silva-Díaz E, Pérez-Ferriols A, Prieto-Torres L, Zayas A, Parera-Amer ME, Pérez A, Aspe L, Román C, Sánchez-Caminero MP, Bassas-Vila J, Domínguez-Auñón JD, Calzado L, Navedo M, Ortiz-Prieto A, Servitje O, Polo-Rodríguez I, Torres I, Hernández-Hernández MN, Mitxelena-Eceiza J, García-Vázquez A, García-Doval I, Ortiz-Romero PL. Falkenhain-López D, et al. Among authors: izu r. Actas Dermosifiliogr. 2023 Apr;114(4):291-298. doi: 10.1016/j.ad.2022.11.010. Epub 2022 Dec 15. Actas Dermosifiliogr. 2023. PMID: 36529273 Free article. English, Spanish.
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).
Daudén E, de la Cueva P, Salgado-Boquete L, Llamas-Velasco M, Fonseca E, Pau-Charles I, Asensio D, Guilà M, Carrascosa JM; DIMESKIN 1 Study investigators. Daudén E, et al. Dermatol Ther (Heidelb). 2023 Jan;13(1):329-345. doi: 10.1007/s13555-022-00863-2. Epub 2022 Dec 1. Dermatol Ther (Heidelb). 2023. PMID: 36456890 Free PMC article.
48 results